Dr. Jennifer Doudna: Uncovering the Ancient Roots of Gene Editing
Nobel Laureate & Founder of the Innovative Genomics Institute (IGI)
April 2026 Breakthrough:
The Doudna Lab has reported the discovery of VIPR systems, a more ancient precursor to CRISPR that uses a “noncontiguous code” for programmable genetic control.
In 2026, Dr. Jennifer Doudna continues to push the boundaries of molecular biology, moving beyond the canonical CRISPR-Cas9 systems that earned her the Nobel Prize. Her latest work focuses on Viral Interference Programmable Repeat (VIPR) systems. This discovery reveals a new logic for programmable genetic control, suggesting that adaptive immunity roots lie in ancient viral warfare far older than previously understood.
Primary Research Publication: April 2026
“A Noncontiguous Code for RNA-Guided DNA Recognition Preceded CRISPR”
Published in bioRxiv / Science (April 27, 2026)
Abstract Summary: This paper reports the discovery of VIPR systems consisting of proteins more ancient than CRISPR-Cas. Unlike standard guide RNAs that require uninterrupted sequences, VIPR uses vrRNAs that recognize double-stranded DNA through a gapped recognition sequence. This allows for programmable transcriptional repression and suggests a triplex-driven mechanism for DNA binding.
Structural Basis of VIPR Recognition
In a companion study, “Triplex formation drives noncontiguous VIPR RNA-guided DNA recognition” (Yoon et al., 2026), Dr. Doudna’s team utilized cryo-electron microscopy to reveal 21 structures of the VIPR assembly pathway. The research establishes how triplex-driven “target-strand handoff” serves as a highly elegant mechanism for programmable nucleic acid recognition.
Trending FAQ: What is the VIPR system in biotech?
Answer: VIPR (Viral Interference Programmable Repeat) is a newly discovered programmable genetic tool identified by the Jennifer Doudna Lab in 2026. It is considered a primitive ancestor to CRISPR. Its primary advantage is the “noncontiguous code,” which offers a different logic for gene silencing and transcriptional control that may overcome the limitations of current CRISPR-Cas9 technologies.
About Dr. Jennifer Doudna
Jennifer Doudna is a Professor of Chemistry and of Molecular and Cell Biology at UC Berkeley. She has co-founded several leading biotech firms, including Mammoth Biosciences, Caribou Biosciences, and Scribe Therapeutics. In 2026, her work continues to focus on making gene therapies like those for Sickle Cell Disease more accessible and affordable globally.